Viral RNA synthesis machinery (RTC) (RTC)

The viral RNA synthesis machinery is a multi-protein assembly essential for the replication and transcription of viral RNA genomes within a host cell [2, 4]. This complex typically centers on the RNA-dependent RNA polymerase (RdRp), which catalyzes the synthesis of new RNA strands from an RNA template [5, 9]. In addition to the polymerase, the machinery often incorporates accessory proteins such as helicases for unwinding RNA structures, methyltransferases for RNA capping, and nucleases that facilitate the acquisition of host-derived primers [3, 6, 10]. Because host cells lack a direct functional equivalent to the viral RdRp, this machinery is a primary target for both broad-spectrum and virus-specific antiviral drugs [1, 11]. Therapeutic agents targeting this machinery, such as remdesivir and sofosbuvir, act as nucleoside or nucleotide analogues that cause premature chain termination or induce lethal mutagenesis, effectively halting viral propagation [5, 12, 17]. Other inhibitors may target allosteric sites on the polymerase or block essential accessory functions like the 'cap-snatching' mechanism used by influenza viruses [9, 14]. Despite its success as a drug target, the high mutation rate inherent to viral RNA synthesis poses a significant challenge, often leading to the rapid emergence of drug-resistant variants [9, 18]. Furthermore, ensuring selectivity to avoid inhibiting host cellular polymerases, such as mitochondrial RNA polymerase, remains a critical safety consideration in drug development [5, 11].

Other names

Viral replication complexReplication-transcription complexViral RNA replicaseViral RNA polymerase complexViral ribonucleoprotein complexvRNP complex

The viral RNA synthesis machinery is targeted by drugs that inhibit its enzymatic activities through several mechanisms: nucleoside and nucleotide analogues (e.g., remdesivir, sofosbuvir) act as alternative substrates that cause premature RNA chain termination [1, 5, 12]; mutagenic agents (e.g., molnupiravir, favipiravir) induce an unsustainable frequency of mutations leading to 'error catastrophe' [5, 9, 11]; non-nucleoside inhibitors bind to allosteric sites to disrupt conformational changes required for catalysis [9, 11]; and specific inhibitors (e.g., baloxavir marboxil) block accessory functions such as the 'cap-snatching' endonuclease activity [14].